{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:03:02Z","timestamp":1792789382457,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Stiftung f\u00fcr angewandte Krebsforschung (SAKF) Zurich","award":["SAKF; F-86901-63-01"],"award-info":[{"award-number":["SAKF; F-86901-63-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>In patients with oligometastatic non-small-cell lung cancer (NSCLC), systemic therapy in combination with local ablative treatment of the primary tumour and all metastatic sites is associated with improved prognosis. For patient selection and treatment allocation, further knowledge about the molecular characteristics of the oligometastatic state is necessary. Here, we performed a genetic characterization of primary NSCLC and corresponding brain metastases (BM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We retrospectively identified patients with oligometastatic NSCLC and synchronous (&amp;lt;3\u2009months) or metachronous (&amp;gt;3\u2009months) BM who underwent surgical resection of both primary tumour and BM. Mutation profiling of formalin-fixed paraffin-embedded tumour cell blocks was performed by targeted next-generation sequencing using the Oncomine Focus Assay panel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Sequencing was successful in 46 paired samples. An oncogenic alteration was present in 31 primary tumours (67.4%) and 40 BM (86.9%). The alteration of the primary tumours was preserved in the corresponding BM in 29 out of 31 cases (93.5%). The most prevalent oncogenic driver in both primary tumours and BM was a KRAS (Kirsten rat sarcoma viral oncogene) mutation (s\u2009=\u200921). In 16 patients (34.8%), the BM harboured additional oncogenic alterations. The presence of a private genetic alteration in the BM was an independent predictor of shorter overall survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In oligometastatic NSCLC, BM retain the main genetic alterations of the primary tumours. Patients may profit from targeted inhibition of mutated KRAS. Additional private genetic alterations in the BM are dismal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejcts\/ezae217","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T21:33:05Z","timestamp":1716586385000},"source":"Crossref","is-referenced-by-count":3,"title":["Genetic profiles of oligometastatic non-small-cell lung cancer and corresponding brain metastases"],"prefix":"10.1093","volume":"65","author":[{"given":"Raphael S","family":"Werner","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Rechsteiner","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Pathology, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Pathology, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Curioni-Fontecedro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-4474","authenticated-orcid":false,"given":"Luca","family":"Regli","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Mairinger","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Essen , Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-9040","authenticated-orcid":false,"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Hospital Zurich , Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soltermann","sequence":"additional","affiliation":[{"name":"Pathologie L\u00e4nggasse , Ittigen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"2024060920401671100_ezae217-B1","author":"Wild","year":"2020"},{"key":"2024060920401671100_ezae217-B2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3322\/caac.21695","article-title":"Cancer statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024060920401671100_ezae217-B3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","article-title":"2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol"},{"key":"2024060920401671100_ezae217-B4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024060920401671100_ezae217-B5","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024060920401671100_ezae217-B6","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer\u2014a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024060920401671100_ezae217-B7","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jtho.2019.05.037","article-title":"Defining synchronous oligometastatic non-small cell lung cancer: a systematic review","volume":"14","author":"Giaj-Levra","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024060920401671100_ezae217-B8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2018.07.042","article-title":"Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study","volume":"124","author":"Chouaid","year":"2018","journal-title":"Lung Cancer"},{"key":"2024060920401671100_ezae217-B9","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024060920401671100_ezae217-B10","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now197","article-title":"Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024060920401671100_ezae217-B11","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024060920401671100_ezae217-B12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ctrv.2018.05.015","article-title":"Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment","volume":"68","author":"El Rassy","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2024060920401671100_ezae217-B13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12874-017-0436-z","article-title":"New methods for estimating follow-up rates in cohort studies","volume":"17","author":"Xue","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2024060920401671100_ezae217-B14","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/ejcts\/ezz384","article-title":"Prognostic factors of oligometastatic non-small-cell lung cancer following radical therapy: a multicentre analysis","volume":"57","author":"Opitz","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"2024060920401671100_ezae217-B15","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","article-title":"Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma","volume":"78","author":"Sili\u0146a","year":"2018","journal-title":"Cancer Res"},{"key":"2024060920401671100_ezae217-B16","doi-asserted-by":"crossref","first-page":"1031094","DOI":"10.3389\/fonc.2022.1031094","article-title":"Lung adenocarcinoma patients with malignant pleural effusions in hot adaptive immunity status have a longer overall survival","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"2024060920401671100_ezae217-B17","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"2024060920401671100_ezae217-B18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12890-023-02354-2","article-title":"Genomic features and its potential implication in bone oligometastatic NSCLC","volume":"23","author":"Liao","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2024060920401671100_ezae217-B19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2021.10.006","article-title":"Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations","volume":"159","author":"Vassella","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024060920401671100_ezae217-B20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-14-1129","article-title":"Next-generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"2024060920401671100_ezae217-B21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2024060920401671100_ezae217-B22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2024060920401671100_ezae217-B23","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024060920401671100_ezae217-B24","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.cllc.2017.05.017","article-title":"Isolated brain metastases as the first relapse after the curative surgical resection in non-small-cell lung cancer patients with an EGFR mutation","volume":"19","author":"Sadoyama","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2024060920401671100_ezae217-B25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ejca.2015.06.107","article-title":"Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma","volume":"51","author":"Preusser","year":"2015","journal-title":"Eur J Cancer"},{"key":"2024060920401671100_ezae217-B26","doi-asserted-by":"crossref","first-page":"672612","DOI":"10.3389\/fonc.2021.672612","article-title":"KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"key":"2024060920401671100_ezae217-B27","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2024060920401671100_ezae217-B28","doi-asserted-by":"crossref","first-page":"940","DOI":"10.21037\/tlcr-23-97","article-title":"Is adagrasib just another sotorasib?\u2014or, should we differentiate their usage according to patients' clinical presentation?","volume":"12","author":"Oya","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2024060920401671100_ezae217-B29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2024060920401671100_ezae217-B30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","article-title":"Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma","volume":"52","author":"Shih","year":"2020","journal-title":"Nat Genet"},{"key":"2024060920401671100_ezae217-B31","doi-asserted-by":"crossref","DOI":"10.3390\/genes8040116","article-title":"The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects","volume":"8","author":"Nguyen","year":"2017","journal-title":"Genes (Basel)"},{"key":"2024060920401671100_ezae217-B32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-021-00500-y","article-title":"Alternative approaches to target Myc for cancer treatment","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2024060920401671100_ezae217-B33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"2024060920401671100_ezae217-B34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jtcvs.2018.02.108","article-title":"Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer","volume":"156","author":"Okiror","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024060920401671100_ezae217-B35","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1038\/s41467-022-33365-y","article-title":"The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/advance-article-pdf\/doi\/10.1093\/ejcts\/ezae217\/57909389\/ezae217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/65\/6\/ezae217\/58178472\/ezae217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/65\/6\/ezae217\/58178472\/ezae217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T20:40:44Z","timestamp":1717965644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezae217\/7682376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezae217","relation":{},"ISSN":["1873-734X"],"issn-type":[{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,25]]},"article-number":"ezae217"}}